NCT03709745View on ClinicalTrials.gov

Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

PHASE4CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

October 18, 2018

Primary Completion Date

October 15, 2021

Study Completion Date

July 10, 2022

Conditions
Branch Retinal Vein Occlusion with Macular Edema
Interventions
DRUG

Aflibercept Injection [Eylea]

Intravitreal injection is given as described in the arm description

DRUG

Ranibizumab Injection [Lucentis]

Intravitreal injection is given as described in the arm description

Trial Locations (1)

11282

St Eriks Eye Hospital, Stockholm

All Listed Sponsors
lead

St. Erik Eye Hospital

OTHER

NCT03709745 - Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion | Biotech Hunter | Biotech Hunter